NCT03042325 is a Phase 4 clinical trial of Alogliptin in Diabetes Mellitus, Type 2, sponsored by Takeda.

Who is sponsoring NCT03042325?

NCT03042325 is sponsored by Takeda.

What drugs are being tested in NCT03042325?

Interventions in NCT03042325: Alogliptin.

What condition does NCT03042325 study?

NCT03042325 studies Diabetes Mellitus, Type 2.

Is NCT03042325 still recruiting?

NCT03042325 is currently withdrawn. Last updated 20 October 2017.

Last reviewed 2017-10-20 · How we verify

NCT03042325

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of Alogliptin in Indian Participants With Type 2 Diabetes Mellitus

Withdrawn Phase 4 Last updated 20 October 2017

What this trial tests

Phase 4 trial testing Alogliptin in Diabetes Mellitus, Type 2. Withdrawn.

Timeline

30 July 2017

Primary endpoint
15 January 2018

15 January 2018

Quick facts

Lead sponsor	Takeda
Phase	Phase 4
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Start date	30 July 2017
Primary completion	15 January 2018
Estimated completion	15 January 2018

Drugs / interventions tested

Alogliptin (ALOGLIPTIN) — full drug profile →

Conditions studied

Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Takeda — full company profile →

Who can join

18 and older, any sex, with Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety and efficacy of alogliptin tablets when given as monotherapy or add on therapy in participants who are on standard care for management of Type 2 Diabetes Mellitus (T2DM).

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Signaling pathways and intervention for therapy of type 2 diabetes mellitus.
Cao R, Tian H, Zhang Y, Liu G, et al · · 2023 · cited 30× · PMID 37303813 · DOI 10.1002/mco2.283

Verify or expand the search:

Other trials of Alogliptin

Trials testing the same drug.

NCT03499704 — A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Ina · Phase 4 · completed
NCT03794336 — Efficacy and Safety of Alogliptin vs. Acarbose in Chinese Type 2 Diabetes Mellitus (T2DM) Patients With High CV Risk or · Phase 4 · completed
NCT05782192 — SAL067 Treatment in Patients With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise · Phase 3 · completed
NCT03501277 — A Study to Determine the Bioequivalence of Alogliptin and Pioglitazone When Administered as Individual Tablets and as Fi · Phase 1 · completed
NCT03231709 — Treatment Preference for Weekly Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Versus Daily DPP-4 Inhibitors in Participants · Phase 4 · completed

Other recruiting trials for Diabetes Mellitus, Type 2

Currently open trials in the same condition.

NCT07415954 — A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 · Phase 2 · recruiting
NCT07532863 — A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Part · recruiting
NCT07336329 — Continuous Glucose Monitoring in Non-Insulin Treated Type 2 Diabetes: Continuous vs. Periodic Use · NA · recruiting
NCT07242469 — A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) · Phase 1 · recruiting
NCT07444203 — Transformative Research in Diabetic Nephropathy 2.0 · recruiting

Other Takeda trials

Trials by the same sponsor.

NCT05669729 — A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velagluceras · not yet recruiting
NCT07403968 — A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease · Phase 2 · not yet recruiting
NCT07293364 — A Study to Learn About the C1-Inhibitor Function as Diagnosis for Hereditary Angioedema · NA · not yet recruiting
NCT07218393 — A Study About the Diagnosis and Management of Hereditary Angioedema (HAE) in Egypt · not yet recruiting
NCT07445087 — A Study of Takhzyro in Teenagers and Adults With Hereditary Angioedema (HAE) in South Korea · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03042325 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Takeda
Last refreshed: 20 October 2017

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03042325.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing